The poor reader of today’s news is bombarded by articles hyping AI or their doom and gloom opposite. This dichotomy exists even in biopharma. Grand proclamations of the technology’s ability to accelerate novel drugs to market or sift through the scientific literature to find undiscovered targets run alongside articles that rail about how artificial intelligence…
